Joel Holiner, MD
Psychiatry · Dallas, TXNPI 1639174246
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $751,494 of the $947,669 with a category attached, or 79.3%. 40 manufacturers reported payments, led by ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) at 32.0% of the total. Among psychiatry clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,859 payments — averaging $509.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$303K
- Teva Pharmaceuticals USA, Inc.$259K
- Supernus Pharmaceuticals, Inc.$94K
- Axsome Therapeutics, Inc.$79K
- Alkermes, Inc.$48K
- Eisai Inc.$30K
- plus $135K from 34 others
What the payments were for
- Consulting fees$84,7319%
- Speaking & faculty fees$751,49479%
- Travel & lodging$62,6307%
- Food & beverage$48,3095%
- Education$5040%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$298,518
- Austedo XR$151,630
- LYBALVI$125,429
- QELBREE$84,338
- AUSTEDO$78,231
- Auvelity$77,440
- ARISTADA$57,747
- Dayvigo$29,659
- UZEDY$23,992
- Dyanavel XR$23,214
- Quillivant$22,643
- Quillichew ER$22,643
- Fanapt$16,770
- INGREZZA$14,448
- ARISTADA INITIO$14,437
- Xelstrym$11,840
- Azstarys$9,444
- QUVIVIQ$7,789
- REXULTI$7,065
- SPRAVATO$4,167
How this compares
$947,669 in reported general payments places this provider in the 95th percentile of 2,238 psychiatry providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 17 | $134,518 |
| CaplytaLumateperone Tosylate | 29 | $51,036 |
| Abilify MaintenaAripiprazole | 13 | $33,982 |
| RexultiBrexpiprazole | 13 | $32,253 |
| EmsamSelegiline | 13 | $26,772 |
| VyvanseLisdexamfetamine Dimesylate | 49 | $19,505 |
| BelsomraSuvorexant | 37 | $17,664 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 155 | $17,170 |
| AuvelityDextromethorphan Hbr/Bupropion | 12 | $12,518 |
| Lisdexamfetamine Dimesylate | 54 | $11,415 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 185 | $10,500 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 333 | $9,312 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 22 | $8,632 |
| Aripiprazole | 69 | $8,379 |
| Clozapine | 75 | $7,763 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $15,618 | $134,51817 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $7,771 | $66,23526 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $303,235 | $51,03629 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix | $32 | $26,04764 claims |
| MerckBelsomra | $114 | $17,66437 claims |
| Axsome Therapeutics, Inc.Auvelity | $79,106 | $12,51812 claims |
| Indivior Inc.Suboxone | $2,224 | $8,63222 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Dallas
- Augustus RushDallas$760K
- Darin OkudaDallas$402K
- Stephen VobachDallas$278K
- Carolyn RekerdresDallas$259K
- Madhukar TrivediDallas$209K
- Ella DalyDallas$67K
- Rakesh JainLake Jackson$7.2M
- Arvinder Pal WaliaAustin$2.5M
- Suresh SureddiPlano$2.2M
- Martin GuerreroEl Paso$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.